Bianchetti Davide, Salvador Nunes Luis, André Pascal, Schoepfer Alain, Moradpour Darius, Chtioui Haithem
Service de gastroentérologie et d'hépatologie, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Service de pharmacologie clinique, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Rev Med Suisse. 2022 Aug 31;18(793):1588-1593. doi: 10.53738/REVMED.2022.18.793.1588.
Azathioprine keeps an important place in the treatment of inflammatory bowel disease and autoimmune hepatitis. This molecule has a narrow therapeutic margin, associated with a risk of toxicity, particularly hematological and hepatic. Its complex metabolism is subject to genetic polymorphisms that are reflected in the inter-individual variability observed in the response to treatment and its tolerance profile. Hence, its use requires a good knowledge of this molecule. Treatment is initiated after a preliminary workup, followed by a progressive titration of the dosage while closely monitoring possible toxicities. Monitoring of blood levels of metabolites (including active ones) helps guide personalized dose adjustment.
硫唑嘌呤在炎症性肠病和自身免疫性肝炎的治疗中占据重要地位。该分子的治疗窗较窄,伴有毒性风险,尤其是血液学和肝脏方面的毒性。其复杂的代谢过程受基因多态性影响,这在治疗反应和耐受性方面的个体间差异中有所体现。因此,使用该药物需要对其有充分了解。治疗在初步检查后开始,随后逐步滴定剂量,同时密切监测可能出现的毒性。监测代谢物(包括活性代谢物)的血药浓度有助于指导个性化的剂量调整。